NCT00353964 is a Phase 2 clinical trial of rEV131 in Ocular Inflammation, sponsored by Evolutec Group.

Who is sponsoring NCT00353964?

NCT00353964 is sponsored by Evolutec Group.

What drugs are being tested in NCT00353964?

Interventions in NCT00353964: rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle.

What condition does NCT00353964 study?

NCT00353964 studies Ocular Inflammation.

Is NCT00353964 still recruiting?

NCT00353964 is currently status unknown. Last updated 27 July 2006.

Last reviewed 2006-07-27 · How we verify

NCT00353964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery

Status unknown Phase 2 Last updated 27 July 2006

What this trial tests

Phase 2 trial testing rEV131 in Ocular Inflammation. Status unknown.

Quick facts

Lead sponsor	Evolutec Group
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Sites	1 location across United States

Drugs / interventions tested

rEV131 — full drug profile →
Prenisolone sodium phosphate 1.0% — full drug profile →
rEV131 vehicle — full drug profile →

Conditions studied

Ocular Inflammation — all drugs for Ocular Inflammation →

Sponsor

Evolutec Group — full company profile →

Who can join

18 and older, any sex, with Ocular Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ocular Inflammation

Currently open trials in the same condition.

NCT05668455 — Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses) · Phase 3 · recruiting
NCT04371445 — Dextenza in the Post-op Management of Vitreoretinal Surgeries · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00353964 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Evolutec Group
Last refreshed: 27 July 2006

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00353964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing